1. Home
  2. ELUT vs MCRB Comparison

ELUT vs MCRB Comparison

Compare ELUT & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ELUT
  • MCRB
  • Stock Information
  • Founded
  • ELUT 2015
  • MCRB 2010
  • Country
  • ELUT United States
  • MCRB United States
  • Employees
  • ELUT N/A
  • MCRB N/A
  • Industry
  • ELUT Medical Specialities
  • MCRB Biotechnology: Pharmaceutical Preparations
  • Sector
  • ELUT Health Care
  • MCRB Health Care
  • Exchange
  • ELUT Nasdaq
  • MCRB Nasdaq
  • Market Cap
  • ELUT 94.0M
  • MCRB 81.2M
  • IPO Year
  • ELUT 2020
  • MCRB 2015
  • Fundamental
  • Price
  • ELUT $2.08
  • MCRB $7.06
  • Analyst Decision
  • ELUT Strong Buy
  • MCRB Hold
  • Analyst Count
  • ELUT 2
  • MCRB 5
  • Target Price
  • ELUT $8.00
  • MCRB $73.67
  • AVG Volume (30 Days)
  • ELUT 38.7K
  • MCRB 146.8K
  • Earning Date
  • ELUT 05-08-2025
  • MCRB 05-07-2025
  • Dividend Yield
  • ELUT N/A
  • MCRB N/A
  • EPS Growth
  • ELUT N/A
  • MCRB N/A
  • EPS
  • ELUT N/A
  • MCRB 0.03
  • Revenue
  • ELUT $23,711,000.00
  • MCRB N/A
  • Revenue This Year
  • ELUT $39.35
  • MCRB N/A
  • Revenue Next Year
  • ELUT $61.26
  • MCRB N/A
  • P/E Ratio
  • ELUT N/A
  • MCRB $213.09
  • Revenue Growth
  • ELUT N/A
  • MCRB N/A
  • 52 Week Low
  • ELUT $1.79
  • MCRB $7.18
  • 52 Week High
  • ELUT $5.24
  • MCRB $30.60
  • Technical
  • Relative Strength Index (RSI)
  • ELUT 43.18
  • MCRB 33.07
  • Support Level
  • ELUT $1.79
  • MCRB $8.92
  • Resistance Level
  • ELUT $2.44
  • MCRB $9.97
  • Average True Range (ATR)
  • ELUT 0.22
  • MCRB 1.08
  • MACD
  • ELUT 0.00
  • MCRB -0.06
  • Stochastic Oscillator
  • ELUT 46.27
  • MCRB 10.61

About ELUT Elutia Inc.

Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.

About MCRB Seres Therapeutics Inc.

Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.

Share on Social Networks: